Global Erythropoietin (EPO) Market Outlook 2017-2021

Market Research

Erythropoietin (EPO) 2017 report studies in Global Market, especially in Europe, North America, South America, Asia (Excluding China), China and ROW, with definitions, classifications, applications and industry chain structure, development trends, competitive landscape analysis, and key regions development and import/export status to 2021.



Erythropoietin, also known as EPO, hematopoietin, or hemopoietin, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine (protein signaling molecule) for erythrocyte (red blood cell) precursors in the bone marrow. Human EPO has a molecular weight of 34 kDa.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Exogenous erythropoietin can be provided to people whose kidneys cannot make enough. Recombinant human erythropoietin (rhEPO) is produced by recombinant DNA technology in cell culture. Several different pharmaceutical agents are available with a variety of glycosylation patterns and are collectively called erythropoiesis-stimulating agents (ESA). Major examples are epoetin alfa and epoetin beta. The specific details for labeled use vary between the package inserts, but ESAs have been used in the treatment of anemia in chronic kidney disease, anemia in myelodysplasia, and in anemia from cancer chemotherapy. Boxed warnings include a risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor recurrence. rhEPO has been used illicitly as a performance-enhancing drug; it can often be detected in blood, due to slight differences from the endogenous protein, for example, in features of posttranslational modification.

This report provides detailed analysis of worldwide markets for Erythropoietin (EPO) from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Erythropoietin (EPO) market and further lays out an analysis of the factors influencing the supply/demand for Erythropoietin (EPO), and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

GCC’s report, Global Erythropoietin (EPO) Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Erythropoietin (EPO) market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Erythropoietin (EPO) market are Amgen (USA), Johnson & Johnson (USA), Roche (Switzerland), Kyowa Hakko Kirin (Japan), 3SBIO (China), among others.

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Erythropoietin (EPO) industry has been provided.

Table of Contents

“Part 1. Exclusive Summary

Part 2. Methodology
2.1 Research Methodology
2.2 Geographic Scope
2.3 Years Considered

Part 3. Introduction
3.1 Definition
3.2 Supply Chain Structure
3.2.1 Raw Material Supply
3.2.2 Traders & Distributors
3.2.3 Key Customers
3.3 Manufacture
3.3.1 Manufacturing Process
3.3.2 Production Cost

Part 4. Market Landscape
4.1 Global Erythropoietin (EPO) Market Size (Volume) 2011-2016
4.1.1 Overview
4.1.2 Global Erythropoietin (EPO) Production
4.1.3 Top 10 Erythropoietin (EPO) Companies (Volume Share)
4.2 Global Erythropoietin (EPO) Market Size (Value) 2011-2016
4.2.1 Overview
4.2.2 Global Erythropoietin (EPO) Production Value
4.2.3 Top 10 Erythropoietin (EPO) Companies (Revenue Share)

Part 5. Segmentation by Products
5.1 Type 1
5.2 Type 2
5.3 Type 3

Part 6. Segmentation by End-users
6.1 Customer Segment 1
6.2 Customer Segment 2
6.3 Customer Segment 3
6.4 Customer Segment 4

Part 7. Geographical Segmentation
7.1 North America Erythropoietin (EPO) Market
7.1.1 North America Market Overview
7.1.2 North America Price & Margin
7.1.3 North America Trade Balance
7.2 EMEA Erythropoietin (EPO) Market
7.2.1 EMEA Market Overview
7.2.2 EMEA Price & Margin
7.2.3 EMEA Trade Balance
7.3 Asia Pacific Erythropoietin (EPO) Market
7.3.1 Asia Pacific Market Overview
7.3.2 Asia Pacific Price & Margin
7.3.3 Asia Pacific Trade Balance

Part 8. Market Forecast
8.1 Market Size by Volume 2016-2021
8.1.1 North America
8.1.2 EMEA
8.1.3 Asia-Pacific
8.1.4 RoW
8.2 Market Size by Value 2016-2021
8.2.1 North America
8.2.2 EMEA
8.2.3 Asia-Pacific
8.2.4 RoW
8.3 Regional Consumption Forecast
8.3.1 North America
8.3.2 EMEA
8.3.3 Asia-Pacific
8.3.4 RoW
8.4 Consumption Forecast by End-users
8.5 Consumption Forecast by Products

Part 9. Company Profiles
9.1 Company A
9.1.1 Overview
9.1.2 Products Offered
9.1.3 Business Performance
9.2 Company B
9.3 Company C
9.4 Company D

Part 10. Market Dynamics
10.1 Market Drivers
10.2 Market Constraints
10.3 Market Strategies

Part 11. Competitive Landscape
11.1 Mergers & Acquisitions
11.2 New Product Launches
11.3 Expansions
11.4 Other Developments

Part 12. Appendix


Inquiry Before Buying



Request For Sample